U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07676097) titled 'Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study' on June 24.
Brief Summary: The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating:
1. Fractional flow reserve (FFR) and
2. Detection of coronary microvascular disease (CMD)
SMARTFLOW is a prospective, single-arm, observational multicenter study of patients with suspected coronary artery disease (CAD) undergoing clinically indicated invasive coronary angiography with physiological assessment. The study is designed to prospectively enroll patient cohorts and collect...